Refine by
Drug Screening In Drug Resistant Articles & Analysis
106 news found
This co-culture system also simulates tumour heterogeneity and evolutionary processes, providing an ideal platform for investigating CAF-mediated drug resistance, immune suppression and barriers to efficient drug delivery. ...
The Centers for Disease Control and Prevention (CDC) reports there are an estimated 450,000 cases of shigellosis, an infection caused by Shigella bacteria, in the United States each year. Unfortunately, a growing number of these infections involve drug-resistant Shigella. The four species of Shigella listed by the CDC include: Shigella sonnei (the most common species in the United States) ...
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the expansion of its custom services to include the synthesis of Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles (MNPs). These customized magnetic particles can be conjugated with the biologically targeted small molecules desired by researchers, and have a uniform size and shape, ...
Profacgen, a leading provider of custom biotechnology services, is pleased to announce significant updates to its Antimicrobial Peptides (AMPs) Services, enhancing its capabilities to support the growing demand for alternative therapies in the fight against drug-resistant pathogens. As antibiotic resistance continues to pose a global health threat, Profacgen is expanding its services to assist ...
The rise of antibiotic-resistant bacteria has driven renewed interest in alternative treatments, including phage therapy. A recent study by Yang, F., et al (2024) explores the potential of bacteriophage therapy for treating multi-drug resistant Mycobacterium tuberculosis (Mtb) infections using humanized mouse models. This study highlights the efficacy of phage DS6A in reducing Mtb load ...
In the ever-evolving landscape of biomedical research and public health, CD Formulation has emerged as a crucial player, offering comprehensive antiserum preparation services. This innovative company supports projects from conception to product launch, making significant strides in the fields of antivirals, antibacterials, and antitoxins. CD Formulation's antiserum preparation services cater to a ...
The New York City Department of Health and Mental Hygiene (NYC Health) warns that tuberculosis (TB) is still a life-threatening problem in the city. As recently as 2022, the agency reports there were 536 confirmed TB cases, including some involving multi-drug resistant (MDR) TB, and that 100% of NYC neighborhoods had at least one TB case. TB is caused by a bacterium known as Mycobacterium ...
It plays a crucial role in drug design and screening, as it enables modeling and prediction of interactions between proteins and small molecules, allowing customers to better understand drug mechanisms of action and optimize candidate compounds. ...
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
Candida auris is an emerging multidrug-resistant microorganism that was first identified in 2009 in Asia. It has quickly become a cause of severe infections around the world, including in the United States according to the Centers for Disease Control and Prevention (CDC). It is as yeast, which is a type of fungi. CDC describes Candida auris as a concerning drug-resistant fungus because it is: ...
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. In this preclinical study: continuous delivery of lenalidomide resulted in improvements in the ...
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. The company launches the drug-resistant metabolomics research service for oncology research and infectious disease studies regarding drug resistance. Drug therapy is one of the ...
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The company has launched the Phage Whole-Genome Sequencing to help discover biomarkers and develop non-antibiotic treatment methods. Phages ...
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. These results were presented at the recent Swiss Society for Microbiology (SSM) Annual Congress 2022 in Lausanne, Switzerland. ...
Canadian life sciences company, Ondine Biomedical Inc. (LON: OBI), this week presented an in vitro study at the World Anti-Microbial Resistance Congress, in Maryland, USA on the effectiveness of its photodisinfection technology against the group of highly infectious and antibiotic-resistant bacteria known as ESKAPE pathogens.[i] ESKAPE pathogens are the most virulent and dangerous pathogens ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. Ms. Clyde is a highly experienced global business executive with an exceptional ...
Several years ago, the Centers for Disease Control and Prevention (CDC) announced it was establishing the Antibiotic Resistance Laboratory Network (AR Lab Network) in Puerto Rico and all 50 states. It was designed to help detect new forms of drug resistance as novel fungal threats emerge. Specifically mentioned in the announcement was Candida auris. CDC reported that this fungus poses a unique ...